Signals in the Activation of Opioid µ-Receptors by Loperamide to Enhance Glucose Uptake into Cultured C2C12 Cells

I. M. Liu; S. S. Liou; W. C. Chen; P. F. Chen; J. T. Cheng

doi:10.1055/s-2004-814449

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2004; 36(4): 210-214
DOI: 10.1055/s-2004-814449

Original Basic

Signals in the Activation of Opioid µ-Receptors by Loperamide to Enhance Glucose Uptake into Cultured C₂C₁₂ Cells

I. M. Liu¹ , S. S. Liou¹ , W. C. Chen² , P. F. Chen³ , J. T. Cheng³

¹The Department of Pharmacy, Tajen Institute of Technology, Yen-Pou, Ping Tung Shien, Taiwan 90701, R.O.C.
²The Department of Chinese Medicine, Jin-Ai Municipal Hospital, Taipei City, Taiwan 10501, R.O.C.
³The Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City, Taiwan, R.O.C.

Abstract

In an attempt to understand the signal pathways of opioid µ-receptors for glucose metabolism, we used loperamide to investigate the glucose uptake into the myoblast C₂C₁₂ cells. Loperamide enhanced the uptake of radioactive deoxyglucose into C₂C₁₂ cells in a concentration-dependent manner that was abolished in cells pre-incubated with naloxone or naloxonazine at concentrations sufficient to block opioid µ-receptors. Pharmacological inhibition of phospholipase C (PLC) by U73122 resulted in a concentration-dependent decrease in loperamide-stimulated uptake of radioactive deoxyglucose into C₂C₁₂ cells. This inhibition of glucose uptake by U73122 was specific since the inactive congener, U73343, failed to modify loperamide-stimulated glucose uptake. Moreover, both chelerythrine and GF 109203X diminished the action of loperamide at concentrations sufficient to inhibit protein kinase C (PKC). The obtained data suggest that an activation of opioid µ-receptors in C₂C₁₂ cells by loperamide may increase glucose uptake via the PLC-PKC pathway.

Key words

C₂C₁₂ cells - Loperamide - Opioid µ-receptors - Phospholipase C - Protein kinase C

Volltext

Referenzen

References

1 Chevlen E. Opioids: a review. Current Pain & Headache Reports. 2003; 7 15-23
2 Yaksh T L. Pharmacology and mechanisms of opioid analgesic activity. Acta anaesthesiol Scand. 1997; 41 94-111
3 Smith E M. Opioid peptides in immune cells. Advances in Experimental Medicine & Biology. 2003; 521 51-68
4 Curry D L, Li C H. Stimulation of insulin secretion by β-endorphin (1 - 27 and 1 - 31). Life Sci. 1987; 40 2053-2058
5 Locatelli A, Spotti D, Caviezel F. The regulation of insulin and glucagon secretion by opiates: a study with naloxone in healthy humans. Acta Diabetol. 1985; 22 25-31
6 Khawaja X Z, Green I C, Thorpe J R, Titheradge M A. The occurrence and receptor specificity of endogenous opioid peptides with pancreas and liver of the rat. Comparison with brain. Biochem J. 1990; 267 233-240
7 Cheng J T, Liu I M, Tzeng T F, Tsai C C, Lai T Y. Plasma glucose lowering effect of β-endorphin in streptozotocin-induced diabetic rats. Horm Meta Res. 2002; 34 570-576
8 Cheng J T, Liu I M, Tzeng T F, Chen W C, Hayakawa S, Yamamoto T. Release of β-endorphin by caffeic acid to lower plasma glucose in streptozotocin-induced diabetic rats. Horm Metab Res. 2003; 35 251-258
9 Liu I M, Chi T C, Chen Y C, Lu F H, Cheng J T. Activation of opioid µ-receptor by loperamide to lower plasma glucose in streptozotocin-induced diabetic rats. Neurosci Lett. 1999; 265 183-186
10 Tzeng T F, Liu I M, Lai T Y, Tsai C C, Chang W C, Cheng J T. Loperamide increases glucose utilization in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol. 2003; 30 734-738
11 Sheriff S, Fischer J E, Balasubramaniam A. Amylin inhibits insulin-stimulated glucose uptake in C₂C₁₂ muscle cell line through a cholera-toxin-sensitive mechanism. Biochim Biophys Acta. 1992; 1136 219-222
12 Liu I M, Tsai C C, Lai T Y, Cheng J T. Stimulatory effect of isoferulic acid on alpha1A-adrenoceptor to increase glucose uptake into cultured myoblast C₂C₁₂ cell of mice. Auton Neurosci Basic & Clinic. 2001; 88 175-180
13 Heel R C, Brogden R N, Speight T M, Avery G S. Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhea. Drugs. 1978; 15 33-52
14 Crist G H, Xu B, Lanoue F, Lang C H. Tissue-specific effects of in vivo adenosine receptor blocked on glucose uptake in Zucker rats. FASEB J. 1998; 12 1301-1308
15 Martin W R. Opioid antagonists. Pharmacol Rev. 1967; 19 463-521
16 Ling G SF, Simantov R, Clark J A, Pasternak G W. Naloxonazine actions in vivo. Eur J Pharmacol. 1986; 129 33-38
17 Evans A A, Hughes S, Smith M E. Delta-opioid peptide receptors in muscles from obese diabetic and normal mice. Peptides. 1995; 16 361-364
18 Ishizuka T, Cooper D R, Hernandez H, Buckley D, Standaert M, Farese R V. Effects of insulin on diacylglycerol-protein kinase C signaling in rat diaphragm and soleus muscles and relationship to glucose transport. Diabetes. 1990; 39 181-190
19 Van Epps-Fung M, Gupta K, Hardy R W, Wells A. A role for phospholipase C activity in GLUT4-Mediated glucose transport. Endocrinology. 1997; 138 5170-5175
20 Wasserman D H, Zinman B. Exercise in individuals with IDDM. Diabetes Care. 1994; 17 924-937
21 Cheng J T, Liu I M, Chi T C, Tzeng T F, Lu F H, Chang C J. Plasma glucose lowering effect of tramadol in streptozotocin-induced diabetic rats. Diabetes. 2001; 50 2815-2821
22 Xie W, Samoriski G M, McLaughlin J P, Romoser V A, Smrcka A, Hinkle P M, Bidlack J M, Gross R A, Jiang H, Wu D. Genetic alteration of phospholipase C β3 expression modulates behavioral and cellular responses to mu opioids. Proc Natl Acad Sci USA. 1999; 96 10 385-10 390
23 Smallridge R C, Kiang J G, Gist I D, Fein H G, Gallowat R J. U-73 122, an aminosteroid phospholipase C antagonist, noncompetitively inhibits thyrotropin-releasing hormone effects in GH3 rat pituitary cell. Endocrinology. 1992; 131 1883-1888
24 Muto Y, Nagao T, Urushidani T. The putative phospholipase C inhibitor U73122 and its negative control, U73343, elicit unexpected effects on the rabbit parietal cell. J Pharmac Exp Ther. 1997; 282 1379-1388
25 Herbert J M, Augereau J M, Gleye J, Maffrand J P. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1990; 172 993-999
26 Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudent V, Boissin P, Boursier E, Loriolle F, Duhamel L, Charon D, Kirilovsky J. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 266; 1991 15 771-15 781
27 Narita M, Ohnishi O, Nemoto M, Aoki T, Suzuki T. The involvement of phosphoinositide 3-kinase (PI3-Kinase) and phospholipase C gamma (PLC gamma) pathway in the morphine-induced supraspinal antinociception in the mouse. Nihon Shinkei Seishin Yakurigaku Zasshi. 2001; 21 7-14
28 Freye E, Latasch L. Development of opioid tolerance - molecular mechanisms and clinical consequences. Anasthesiol Intensivmed Notfallmed Schmerzther. 2003; 38 14-26
29 Neri L M, Borgatti P, Capitani S, Martelli A M. Protein kinase C isoforms and lipid second messengers: a critical nuclear partnership?. Histol Histopath. 2002; 17 1311-1316
30 Bandyopadhyay G, Standaert M L, Kikkawa U, Ono Y, Moscat J, Farese R V. Effects of transiently expressed atypical (zeta, lambda), conventional (alpha, beta) and novel (delta, epsilon) protein kinase C isoforms on insulin-stimulated translocation of epitope-tagged GLUT4 glucose transporters in rat adipocytes: specific interchangeable effects of protein kinases C-zeta and C-lambda. Biochem J. 1999; 337 461-370

Prof. J.-T. Cheng

Department of Pharmacology · College of Medicine · National Cheng Kung University

Tainan City · Taiwan 70101 · R.O.C.

Telefon: +886(6)2372706

Fax: +886(6)2386548 ·

eMail: jtcheng@mail.ncku.edu.tw